FIELD : medicine; pharmaceuticals.SUBSTANCE : present invention relates to immunology. Disclosed are a bispecific antibody and a fusion protein for specific binding to GD2 and CD3. Also disclosed are pharmaceutical compositions, nucleic acid, an expression vector, a host cell and a method of producing a bispecific antibody. Also described is a method of destroying neuroblastoma cells, a method of inhibiting growth of neuroblastoma and a method for increasing half-life of a bispecific antibody.EFFECT : present invention can find further application in increasing the activity of antibodies mobilizing T-cells for immunotherapy of malignant entities, particularly neuroblastoma.18 cl, 11 dwg, 19 tbl, 6 ex